Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer

NCT01430585 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01430585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01430585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2012
Completion date
December 31, 2012
Enrollment
14 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer (phase 1b), early breast cancer (phase 2)